( June 12, 2026, 3:10 PM EDT) -- LOS ANGELES — A dietary supplement company markets a product as a “natural” alternative or equivalent to prescription diabetes and diet drugs “hoping to cash in on the synthetic GLP-1 agonist craze and swindle Americans, including Californians, into buying its Product,” a woman alleges in a putative class action filed in a California federal court that asserts claims for violation of California’s unfair competition law (UCL) and other laws....